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Abstract
Summary The effect of equivalent oral doses of vitamin D3
600 IU/day, 4200 IU/week and 18,000 IU/month on vitamin
D status was compared in a randomized clinical trial in
nursing home residents. A daily dose was more effective than
a weekly dose, and a monthly dose was the least effective.
Introduction It is assumed that equivalent daily, weekly or
monthly doses of vitamin D3 equally influence vitamin D
status. This was investigated in a randomized clinical trial
in nursing home residents.
Methods The study was performed in ten nursing homes
including 338subjects(76maleand 262 female),witha mean
age of 84 (± SD 6.3 years). They received oral vitamin D3
either 600 IU/day, or 4200 IU/week, or 18,000 IU/month or
placebo. After 4 months, calcium was added during 2 weeks,
320mg/dayor640mg/dayorplacebo.Outcome:serumlevels
of 25-hydroxyvitamin D (25(OH)D), parathyroid hormone
(PTH) and bone turnover markers. Statistical approach: linear
multilevel analysis.
Results At baseline, mean serum 25(OH)D was 25.0 nmol/L
(SD 10.9), and in 98%, it was lower than 50 nmol/L. After
4 months, mean serum 25(OH)D levels increased to
62.5 nmol/L (after daily vitamin D3 69.9 nmol/L, weekly
67.2 nmol/L and monthly 53.1 nmol/L, P<0.001 between
groups). Median serum PTH levels decreased by 23% (p<
0.001). Bone turnover markers did not decrease. Calcium
supplementation had no effect on serum PTH and bone
turnover.
Conclusion Daily vitamin D was more effective than weekly,
and monthly administration was the least effective.
Keywords Calciumsupplementation.
Secondary hyperparathyroidism.VitaminDdeficiency.
VitaminDsupplementation
Introduction
Vitamin D deficiency is common in older persons, in
particular in residents of homes for the elderly and nursing
homes and in patients with hip fracture [1–3]. In these
groups the prevalence of vitamin D deficiency, defined at
that time as serum 25(OH)D<30 nmol/L based on values in
healthy blood donors, was reported to be 75% [3]. This is
mainly explained by the fact that older persons do not often
go outside in the sunshine and dietary vitamin D intake is
low. Vitamin D deficiency causes secondary hyperparathy-
roidism, which leads to cortical bone loss, osteoporosis and
fractures [4]. It may also cause fatigue, muscle weakness,
increased body sway and falls [5, 6] . Vitamin D supple-
mentation in vitamin D deficient elderly increases the
serum concentration of 25-hydroxyvitamin D (25(OH)D)
and decreases the serum concentration of parathyroid
hormone (PTH) [3]. It also decreases wintertime bone loss
from the lumbar spine [7] and increases bone mineral
density of the femoral neck [8]. Vitamin D supplementation
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e-mail: p.lips@vumc.nlcombined with calcium decreased body sway and falls in a
German study [5] and decreased hip as well as other non-
vertebral fractures in French nursing home residents [9],
whereas the results in more healthy elderly, living indepen-
dently in the community were equivocal [10–14].
Vitamin D status in the elderly may be improved by
ultraviolet irradiation [15] or by vitamin D supplementation
[3, 7, 8–14]. Some controversy exists on the required serum
25(OH)D level, but most investigators agree that the level
should be at least 50 or even 75 nmol/l [16, 17].
The Dutch Health Council advises vitamin D 600 IU
daily for elderly of 70 years and older who do not come
outside in the sunshine [18]. Oral vitamin D3 can be taken
once a day but also with longer intervals because of its long
half life, being around 25 days. It is not known whether
equivalent doses once a week or once a month are equally
effective.
A low calcium intake aggravates vitamin D deficiency by
increasingtheturnoverofvitaminDmetabolitesbysecondary
hyperparathyroidism [4]. On the other side, a high calcium
intake does not completely protect against secondary
hyperparathyroidism, and thus cannot compensate for vita-
min D insufficiency [19]. The calcium requirement for
skeletal maintenance is raising with age whereas the capacity
for compensating a low calcium intake declines with age
[20]. In the Netherlands the mean daily calcium intake of
independently living elderly in homes and apartments of the
elderly is about 900 mg [2]. In the guidelines of the Dutch
Health Council, the advised daily amount of calcium for
elderly 70 years and older is 1200 mg [18].
The aim of the present study was to investigate, in a Dutch
nursing home population, whether there is a difference in
efficacy of different doses and intervals of oral vitamin D3
supplementation with the same total dose. A second aim was
to assess the additional effect of calcium supplementation
following vitamin D supplementation on serum PTH and
markers of bone turnover.
Subjects and methods
Subjects
Ten somatic and psychogeriatric nursing homes participated
and 1,006 subjects were invited. Of these, 146 did not
respond, 386 refused to participate and 136 did not meet
inclusion criteria. Participants were 338 (76 male and 262
female) patients of 70 years or older with a mean age of
84years (SD 6.2).Exclusioncriteria weregoingoutside in the
sunshine more than once a week, the use of vitamin D or
calciumsupplementation,theuseofmorethanonevitaminD-
fortified food or drink per day, complete immobilisation and a
very poor life expectancy. Poor cognition was not an
exclusion criterion. This did not affect adherence. Nursing
homes were enrolled in the study throughout the year.
Participants living together in the same nursing home started
the study during the same season. The dietary vitamin D
intake was estimated at about 100 IU/day, based on fish and
margarine consumption. In the Netherlands only margarine is
fortified with vitamin D3 (3 IU/g) and the diet does not
contain vitamin D2. Written informed consent was obtained
from participants or their proxies. The protocol as well as the
patient information letters were approved by the Ethical
Review Board of the VU University medical centre.
Randomisation
Participants were randomised in blocks of six, to receive,
during the study period of four and a half months, either oral
vitamin D3 600 IU/day (one tablet) or placebo, 4200 IU/week
(seven tablets once a week) or placebo or 18,000 IU/month
(one powder once a month) or placebo. (Solvay Pharmaceuti-
cals, Weesp, Netherlands). After four months, participants in
every group were randomised again to receive during 14 days
either calcium carbonate or placebo. The first 156 participants
who were randomised received 800 mg calcium carbonate
(320 mg Ca2+) or placebo, the subsequent 120 participants
received 1,600 mg calcium carbonate (640 mg Ca2+) or
placebo. The study medication was centrally distributed to
ensure compliance. The study was completed by 269 patients.
Measurements
At baseline co-medication was registered and a questionnaire
fordietarycalciumintakewasusedtocalculatethemeandaily
calcium intake from dairy products, underestimating calcium
intake by 200–300 mg/day [2, 21].
The ability of standing and walking was assessed by a
standing score, ranging from 1 (cannot stand alone) to 5 (can
easily get up and remain standing without help) and a walk-
ing score ranging from 1 (cannot do one active step) to 5
(completely independent walking). Both scores have previ-
ously been described [22].
During the study all falls and fractures were registered by
thenursingstaffonspecialformsandcheckedwiththeroutine
incident registration. At the end of each study period in a
nursing home, every ward was asked to complete a
questionnaire on the opinion of the nursing staff about the
suitability of each distribution form, compliance, the risk of
making mistakes, time investment and preferences.
Random samples of the returned medication were counted
in order to verify compliance.
Adequate compliance was defined to exist when more than
80% of the study medication was ingested. Twice a quality
check was madeonthe researchmedication bytakingrandom
samples for determining the vitamin D3 content of tablets and
664 Osteoporos Int (2008) 19:663–671powders. Fasting blood samples were obtained at baseline, at
two and four months.
Serum 25(OH)D was measured by radioimmunoassay
(Diasorin, Stillwater, MN) with an inter-assay coefficient of
variation (CV) of 10% at 30 nmol/L. Serum PTH was
measuredbyradioimmunoassay(Incstar,SanJuanCapistrano,
CA) with an inter-assay CV of 10% at 3.5 pmol/L. Serum
carboxy-terminal collagen crosslinks or CTX, a marker for
bone resorption, was measured by immuno-assay (CrossLaps,
(Roche) with an interassay CVof 5%.
For theseparametersthe sera ofa singleparticipantwere all
measured within the same run to decrease variation. Serum
calcium, phosphate, albumin, creatinine and alkaline phospha-
tase (APh) were measured using standard laboratory proce-
dures, immediately after obtaining the blood samples. Serum
calcium was corrected for serum albumin using the formula:
corrected calcium ðmmol=LÞ¼
measured calcium ½  þ 40   albumin ðg=LÞ ðÞ   0:02
Statistical analysis
Statistical analysis was performed using SPSS 12.0.1. Data
are presented as means (and standard deviation [SD]) or –
in case of skewed distributions – as medians (and
interquartile range [IQR]). Associations between baseline
serum 25(OH)D and PTH, PTH and AF, and AF and CTX
were examined by means of the Pearson correlation
coefficient or – when one or both outcome variables had
a skewed distribution – the Spearman rank order correlation
coefficient. Baseline characteristics of dropouts and com-
pleters were compared by logistic regression analysis.
Linear multilevel analysis with SPSS Mixed Models was
used to investigate: (1) the effect of vitamin D supplemen-
tation on change (from baseline (t0) to 4 months (t2)) in
biochemical outcome variables (serum 25(OH)D, serum
PTH, bone turnover markers) and (2) the effect of
additional calcium supplementation on change (from
4 months (t2) to 4.5 months (t3)) in biochemical outcome
variables, adjusting for possible clustering of observations.
The included levels were repeated measures (i.e., time),
respondent, and nursing home. Nursing home was included
in the final analyses only in case of a change of the effect
size of more than 10%. Separate models were created with
25(OH)D, phosphate, corrected calcium, CTX, PTH, and
APh as the respective dependent variables. We examined
the potential confounding effect of season, age, sex, mean
daily calcium intake, creatinine, standing and walking score
at t0. For PTH and APh, logarithmic transformations were
performed to normalize variance to allow parametric tests.
For these log-transformed outcome variables, the estimated
mean difference between two intervention groups was
transformed back using an antilog transformation. The
resulting estimate is the ratio of the geometric means of the
outcome variable in both intervention groups. The geometr-
ic mean resembles the median. The level of significance
was set at P<0.05.
Results
Baseline characteristics
Table 1 shows the baseline characteristics of the 338
participants enrolled in the study. These were very similar
for the different intervention groups. In the total group,
baseline mean serum 25(OH)D was 25.0 nmol/L (SD 10.9).
In 55% of the participants, serum 25(OH)D was lower than
25 nmol/L while 77% had levels below 30 nmol/L and 98%
below 50 nmol/L (data not shown). Baseline median serum
PTH was 7.2 pmol/L (IQR 5.1–10.5) (ref. values: 1–
11 pmol/L). There were statistically significant correlations
at baseline between serum 25(OH)D and serum PTH values
(r=−0.25; P<0.001), serum PTH and serum APh values (r=
0.16; P<0.01), and serum APh and serum CTX values (r=
0.23; P<0.001) (data not shown). The median daily calcium
intake from dairy products was 750 mg (IQR 560–1035).
Trial schedule
Figure 1 shows the trial schedule as well as the results of
the randomisation procedure of both the vitamin D and the
calcium intervention. Of the 341 participants originally
enrolled, three were enrolled incorrectly because of hyper-
calcemia (corrected serum calcium: 2.69; 2.83; and 2.85),
leaving 338 participants eligible for the study.
Vitamin D intervention
The 338 enrolled participants were randomised to treatment
with vitamin D3 one tablet of 600 IU each day (n=55), a
placebo in the form of one tablet each day (n=57), vitamin
D3 in the form of seven tablets (4200 IU) once a week
(n=54), a placebo in the form of seven tablets once a week
(n=58), vitamin D3 in the form of one powder once a
month (n=57), or a placebo in the form of one powder of
1,800 IU once a month (n=57). The treatment period of
four months was completed by 276 participants. Of the 62
drop-outs, 41 died during the study period and there were
21 withdrawals: nine participants became terminally ill; five
participants became uncooperative to donate a blood
sample; one participant showed signs of discomfort during
blood sampling; one participant became immobile; 3
participants were moved elsewhere; and one participant
dropped out for unknown reasons. Finally, one participant
was excluded from the analyses due to extremely high
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Fig. 1 Flow diagram of
progress through the randomized
clinical trial of vitamin D
supplementation followed by the
randomized clinical trial of
calcium supplementation
Table 1 Characteristicsof338participants at baseline(t0) by intervention group at t0 (Pl D = placebo vitamine D, D = vitamin D) and t2 (Pl Ca = placebo
calcium, Ca = calcium)
Total D total D daily D weeky D monthly Pl D total Ca
b Pl Ca
b
(n=338) (n=166) (n=55) (n=54) (n=57) (n=172) (n=68) (n=71)
% female 77.5 76.5 83.6 72.2 73.7 78.5 76.5 78.9
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (yr) 84.2 (6.2) 84.2 (6.5) 84.3 (6.3) 84.3 (6.4) 83.9 (6.9) 84.2 (5.9) 83.3 (6.2) 84.5 (6.8)
25(OH)D (nmol/L) 25.0 (10.9) 24.9 (10.1) 24.0 (8.6) 26.7 (12.6) 24.1 (8.8) 25.0 (11.7) 25.3 (10.6) 24.1 (9.6)
Calcium corrected
(mmol/L)
2.42 (0.10) 2.42 (0.09) 2.42 (0.09) 2.41 (0.08) 2.42 (0.10) 2.43 (0.10) 2.41 (0.08) 2.42 (0.10)
Phosphate
(mmol/L)
1.03 (0.14) 1.02 (0.14) 1.02 (0.13) 1.02 (0.16) 1.02 (0.13) 1.04 (0.14) 1.01 (0.14) 1.03 (0.13)
CTX (ng/L) 592 (277) 571 (274) 594 (274) 626 (311) 496 (218) 613 (280) 552 (288) 565 (255)
Albumin (g/L) 33.4 (3.3) 33.4 (3.3) 33.0 (3.5) 33.1 (3.4) 34.2 (2.8) 33.4 (3.2) 34.0 (3.2) 33.0 (3.4)
Standing score
(1–5)
3.3 (1.6) 3.3 (1.6) 3.5 (1.6) 3.1 (1.7) 3.5 (1.6) 3.3 (1.6) 3.2 (1.7) 3.5 (1.6)
Walking score
(1–5)
3.0 (1.4) 3.0 (1.4) 3.0 (1.4) 3.0 (1.6) 3.0 (1.3) 3.0 (1.4) 2.9 (1.4) 3.1 (1.4)
Skewed variable Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Calcium intake
(mg/day)
b
750
(560–1035)
750
(594–1015)
725
(623–1039)
755
(550–1028)
788
(583–955)
750
(550–1053)
773
(614–1024)
730
(565–1003)
PTH (pmol/L) 7.2 (5.1–10.5) 7.2 (5.2–10.4) 7.4 (5.2–10.4) 6.7 (5.3–9.9) 7.2 (5.1–10.5) 7.1 (5.1–11.1) 6.5 (5.2–9.4) 7.3 (5.1–10.9)
AF (U/L) 85 (69–102) 86 (71–104) 82 (73–100) 90 (68–106) 87 (67–105) 85 (69–99) 89 (68–105) 82 (67–98)
Creatinine (μmol/L) 93 (81–103) 92 (81–103) 87 (80–95) 96 (85–104) 94 (81–105) 93 (82–105) 91 (80–102) 92 (81–102)
IQR = interquartile range
aFrom dairy products
bWithin participants completing the vitamin D intervention (n=276) treated with vitamin D (n=139)
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Osteoporos Int (2008) 19:663–671 667levels of alkaline phosphatase (278, 1025, 2661 U/L at,
respectively, t0,t 1,t 2) for unknown reasons (further analysis
was refused by the patient). The number of drop-outs did
not differ significantly between the placebo (n=35) and the
v i t a m i nDg r o u p( n=27). Dropouts were similar to
completers with respect to most baseline characteristics
(sex, age, 25(OH)D, corrected calcium, phosphate, albu-
min, standing score, walking score, mean daily calcium
intake, and creatinine), but had higher serum levels of CTX,
and APh (P<0.05) (data not shown).
Calcium intervention
The 276 participants who completed the vitamin D
intervention study were randomised to treatment with
calcium one tablet each day (n=138), or placebo one tablet
each day (n=138). The treatment period of 14 days was
completed by 269 participants. Of the seven drop-outs,
three died, three became terminally ill and one participant
dropped out for unknown reasons. Only those treated with
vitamin D were included in the analysis of the calcium
intervention (n=68 for calcium; n=71 for placebo); there
was only one drop-out in each group.
Effectiveness of Vitamin D supplementation
Nursing home and potential confounding variables at baseline
were not included in the final models since the effect sizes
were hardly influenced by adding these variables.
Serum 25-hydroxyvitamin D
Effects of vitamin D supplementation on serum 25(OH)D in
the various treatment groups are shown in Table 2 and Fig. 2.
The mean difference in increase of serum 25(OH)D was
38.5 nmol/L (95% confidence interval (CI) 25.6–41.5) in
favour of vitamin D when compared to placebo. Daily,
weekly and monthly administration of vitamin D resulted in
increase of serum 25(OH)D when compared to placebo (P<
0.001). The mean difference in increase of serum 25(OH)D
was highest after 4 months with daily administration of
vitamin D (mean 47.2 nmol/l) when compared to weekly
(mean 40.7 nmol/l, P<0.01) and monthly (mean 27.6 nmol/l,
P<0.001) administration. Weekly administration of vitamin D
resulted in a greater increase of serum 25(OH)D than monthly
administration (P<0.001). The percentage of patients with
serum 25(OH)D below cut offs of 25 nmol/l, 50 nmol/l and
75 nmol/l is shown in Table 3. At 4 months, the percentage of
patients with serum 25(OH)D<50 nmol/l was 10.9, 10.6 and
36.4% in the daily, weekly and monthly groups of vitamin D
supplementation respectively.
Secondary outcome measures: serum phosphate
and corrected calcium
Serum phosphate and corrected serum calcium values in-
c r e a s e ds i g n i f i c a n t l ym o r ei nt h ev i t a m i nDg r o u pt h a ni nt h e
placebo group. However, no differences between daily,
weekly, or monthly administration were found (Table 2).
Serum parathyroid hormone and bone turnover markers
Effects of vitamin D supplementation on serum PTH, serum
APh and CTX in the various treatment groups are shown in
Table 2. Serum PTH (P<0.000) decreased in the vitamin D
group from 7.2 to 5.5 pmol/l when compared to placebo,
which is a decrease of 23% (ratio 0.77, 95% CI 0.70–0.85,
P<0.001). The decrease of serum PTH was greater with
daily administration of vitamin D when compared to weekly
(P<0.05) and monthly (P<0.10) administration. The differ-
ence between weekly and monthly administration of vitamin
D was not significant. The serum concentrations of alkaline
phosphatase and CTX did not change following vitamin D
supplementation.
Effectiveness of calcium supplementation
There was no effect of calcium supplementation on any of the
six biochemical outcome variables when compared to
placebo. Also after stratification by administration of vitamin
D (daily, weekly or monthly), an effect of calcium supple-
mentation was not observed except for corrected calcium
levels which increased more in the calcium group than in the
placebo group in the daily dose vitamin D group only (P<
0.05). No effect was found of calcium doses (800 mg vs
1,600 mg calcium carbonate). Adding nursing home and
other potential confounding variables at baseline did not
influence the results.
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The number of falls and fractures did not differ between the
interventiongroupsandthecontrolgroups,whichwasexpected
given the short study period of four and a half months.
Compliance
The compliance assessed within 96 random samples of the
returned medication was good. In the daily administration
group, all 33 participants were compliant–i.e., used at least
80% of the tablets–(median=97.0; IQR 94.5–100). For
weekly administration, 80% of the 35 participants were
compliant–i.e., used at least 80% of the tablets (median=
98.5; IQR 84.0–100). For monthly administration, 93% of
the 28 participants were compliant–i.e., used at least four
out of five powders (median=100; IQR 85.0–100).
Survey nursing staff
A survey among the nursing staffs of the participating nursing
home wards showed a distinct preference (72%) for daily
administration compared to weekly and monthly. Thirty-ning
percentofthenursingstaffsreportedtheimpressionthatfewer
mistakes were made using daily administration instead of
weekly or monthly administration.
Discussion
The results of this study confirm the poor vitamin D status
often observed in institutionalised elderly. In this study,
baseline serum 25(OH)D levels in these nursing home
residents was comparable to those observed in other studies
in institutionalized elderly in the Netherlands [2, 3], resulting
in median serum PTH levels in the upper normal range. A
negative correlation between serum PTH and serum 25(OH)
D was observed, confirming other studies [4].
In all treatment groups oral vitamin D supplementation
appeared to be effective, resulting in increasing serum 25
(OH)D levels and decreasing serum PTH levels as observed
in other studies [3, 4, 23]. However, no effect was seen on
serum alkaline phosphatase and CTX levels.
Daily administration of vitamin D3 was significantly more
effective than weekly and monthly administration. This could
be due to more regular absorption in the gut or better
compliance. The percentage of participants with serum 25
(OH)D<50 nmol/l after four months of supplementation was
about 10% in the daily and weekly groups, but was more than
35%inthemonthlygroup.Anoptionwouldbetoincreasethe
dose when vitamin D is supplemented only once per month.
The dose of 600 IU/day was chosen according to the Dutch
and US recommendations [4, 18]. In order to attain a higher
percentage of people with serum 25(OH)D>50 nmol/l, the
dose of vitamin D should be 700–800 IU/day as was recom-
mended for patients with osteoporosis in a recent review
[24].
The overall decrease of serum PTH was 23% with vitamin
D supplementation, which corresponds to our previous
vitamin D supplementation study in a nursing home [15]
and which is a larger decrease than that observed in healthy
independently living elderly women where the decrease of
serum PTH was 15% [8]. This is consistent with the more
severe vitamin D deficiency and the greater degree of
secondary hyperparathyroidism observed in these, mainly
psychogeriatric, nursing home residents. Improvement of
vitamin D status and suppression of PTH secretion may
reduce bone turnover and bone loss, increase bone mineral-
ization and thereby reducing fracture risk, although this was
not the subject of this study.
For calcium supplementation, calcium citrate, lactate or
carbonate can be used. In this study, calcium carbonate was
used based upon bioavailability, cost and clinical efficacy
[25]. The absorption of calcium from dairy products is about
similar to that from calcium carbonate [26, 27]. Because of
the side effects of calcium carbonate (gastrointestinal
Table 3 Percentage of partic-
ipants with 25(OH)D levels
below a certain cut-off point at
baseline and after vitamin D
or placebo supplementation
Group: Total Placebo Vitamin D
total
Vitamin D
daily
Vitamin D
weekly
Vitamin D
monthly
25(OH)D<25 nmol/L
Baseline (t0) 55.3 56.9 53.6 60.9 48.9 51.1
2 months (t1) 30.1 57.8 2.9 2.2 0.0 6.8
4 months (t2) 27.4 52.6 2.2 2.2 0.0 4.5
25(OH)D<50 nmol/L
Baseline (t0) 97.5 96.4 98.6 100.0 95.7 100.0
2 months (t1) 65.4 94.8 36.5 26.1 19.1 65.9
4 months (t2) 58.0 97.1 19.0 10.9 10.6 36.4
25(OH)D<75 nmol/L
Baseline (t0) 99.6 99.3 100.0 100.0 100.0 100.0
2 months (t1) 95.2 99.3 91.2 87.0 89.4 97.7
4 months (t2) 88.3 100.0 76.6 63.0 72.3 95.5
Osteoporos Int (2008) 19:663–671 669irritation, constipation, belches), possibly more pronounced
in a population of frail elderly with substantial comorbidity
and comedication, one should not choose a too high sup-
plementation dose. Given the expected dietary calcium intake
of about 900 mg per day, two supplementation doses 800 mg
calcium carbonate (320 mg Ca2+) and 1,600 mg calcium
carbonate (640 mg Ca2+), respectively) were used.
The median calcium intake in these Dutch nursing home
residents (750 mg per day from dairy products, total
estimated dietary intake 950–1,000 mg per day) was
slightly lower than the guidelines recommend and relatively
high compared to institutionalised elderly in other
countries, probably due to a higher dairy intake. This was
expected since every Dutch nursing home has its own
dietician. Calcium supplementation combined with vitamin
D in the last part of the study did not lead to a decrease of
biochemical markers of bone turnover. An explanation
might be that immobility is a cause of high bone turnover,
which is not suppressed by calcium supplementation. The
nursing staff’s preference for daily supplementation of
vitamin D is probably due to the fact that it fits better in a
regular distribution routine, is less time consuming and less
susceptible for making mistakes.
In conclusion, 98% of the participants had a baseline
serum 25(OH)D lower than 50 nmol/L. Oral vitamin D3
supplementation, administered daily was more effective
than weekly doses in nursing home residents, while
monthly administration was the least effective, 35% still
having a serum 25(OH)D<50 nmol/l after 4 months
treatment in this group. Calcium supplementation did not
augment the effect of vitamin D supplementation.
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